Although CD19 CAR-T cell therapy brings prolonged survival outcomes and an improved cure rate for RR-DLBCL, it has been reported that more than 50% of nonrelapse mortality in long-term survivors after CAR-T cell therapy is related to infections [29]. Here, CD19 is linked to diffuse large B-cell lymphoma.